Pregled bibliografske jedinice broj: 201159
Genetic polymorphism of CYP2C9 and warfarin dose predicting in anticoagulation therapy
Genetic polymorphism of CYP2C9 and warfarin dose predicting in anticoagulation therapy // Clinical chemistry (Baltimore, Md.), 51(Suppl 6) (2005) (podatak o recenziji nije dostupan, kongresno priopcenje, znanstveni)
CROSBI ID: 201159 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Genetic polymorphism of CYP2C9 and warfarin dose predicting in anticoagulation therapy
Autori
Štefanović, Mario ; Topić, Elizabeta ; Samardžija, Marina
Izvornik
Clinical chemistry (Baltimore, Md.) (0009-9147) 51(Suppl 6)
(2005);
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, kongresno priopcenje, znanstveni
Ključne riječi
CYP2C9 genotyping; warfarin; anticoagulant therapy
Sažetak
Warfarin (racemic mixture of S- and R- enantiomers) is an anticoagulant therapy drug which is often associated with unwanted side effects such as serious bleeding.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
